At least buy stocks that are in an uptrend, or stocks that have tanked on huge shakeout volume, or stocks that have based near their lows for a few months and are ready to breakout.
Getting emotionally attached to a stock and buying more as it slides in a downtrend is for losers.
Kimmie is out of control!
Where does all the money go?
Is he running out of petri dishes?
Paying money for products that burn cash is the road to ruin.
Will it take an additional $20M to launch?
It's a desperate move by Ahn.
"WARREN, N.J., Jan. 16, 2013 -- MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced that it has licensed Zuplenz® (ondansetron) to Vestiq Pharmaceuticals, a specialty pharmaceutical company focused on innovative therapeutic remedies within the supportive care markets. Zuplenz is an oral soluble film (OSF) for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting. The licensing agreement comprised an undisclosed upfront payment from Vestiq, as well as double digit royalty payments from sales of Zuplenz. Vestiq relaunched Zuplenz in the United States in the fourth quarter of 2012."
WHAT HAPPENED TO VESTIQ?
DID THEY WALK AWAY AFTER MAKING AN UPFRONT PAYMENT?
WHY WOULD THEY DO THAT, UNLESS ZUPLENZ SUCKS EVEN MORE THAN ABSTRAL?
Good luck with that!
INO hasn't been able to advance to a completed P3 trial in 35 years.
If you peddle the same failed technolgy, you will get the same results.
The Dhillon boys need to find a new gig.
Punit is a political science major ... he is better suited for running for a political office..
It's tanking because the Dhillon boys are running the Company.
The pps cratered at Inovio when they were there, on massive dilution and reverse splits.
It's tanking because ONCS has NONEXCLUSIVE licensed technology that has failed over and over again.
In 35 years, Inovio bag holders have not seen even one Phase 3 trial, just lots of hype about the never ending mice and petri dish studies.
You will never see a Phase 3 trial completed at ONCS.
They are using the same MO : preclinical hype, conferences, publication, videos ..... to prop up the price before diluted offerings.
PLease read and understand ............. the hedgies shorted and covered with the discounted offering as they have with all the prior offerings. Institutional holdings are less than 1%.
you are officially an imbecile.
Yeah, both stocks tanked.
DNDN is burning $36M per quarter, so they have cash remaining for about a year.
Europe would just add to the burn rate.
in 2016 the convertible notes come due to the tune of $560M.
You are headed for a death spiral.
DNDN = GALE = DUNG
You must be short the stock ..... the road to riches.
INO a stock that just keeps giving to the shorts ...... $200.00 to $9.00.